Carboquone therapy for hematologic neoplasms.
A daily oral dose of 1-2 mg of Carboquone was administered for remission induction to 38 patients with hematologic malignancy, and the following results were obtained: 2 of the 3 patients with malignant lymphoma, 1 of the 12 patients with multiple myeloma, 13 of the 14 patients with chronic myelogenous leukemia, and all 9 patients with polycythemia vera attained complete remission.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001389:Azirines / Q000627:therapeutic use*; D002225:Carbazilquinone / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011087:Polycythemia Vera / Q000188:drug therapy*
D001389:Azirines; D002225:Carbazilquinone